Efprezimod alfa + Methotrexate + Tacrolimus + Placebo
Phase 2Completed 0 watching 0 views this week⚡ Active
52
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Graft Versus Host Disease
Conditions
Graft Versus Host Disease, Hematopoietic Stem Cell Transplantation, Leukemia
Trial Timeline
Sep 19, 2016 → May 18, 2021
NCT ID
NCT02663622About Efprezimod alfa + Methotrexate + Tacrolimus + Placebo
Efprezimod alfa + Methotrexate + Tacrolimus + Placebo is a phase 2 stage product being developed by Merck for Graft Versus Host Disease. The current trial status is completed. This product is registered under clinical trial identifier NCT02663622. Target conditions include Graft Versus Host Disease, Hematopoietic Stem Cell Transplantation, Leukemia.
Hype Score Breakdown
Clinical
17
Activity
12
Company
10
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02663622 | Phase 2 | Completed |
Competing Products
20 competing products in Graft Versus Host Disease
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Prograf + Methotrexate + Cyclosporine | Astellas Pharma | Approved | 85 |
| Alefacept | Astellas Pharma | Phase 2 | 52 |
| tacrolimus | Astellas Pharma | Approved | 85 |
| Tacrolimus + Tacrolimus | Astellas Pharma | Pre-clinical | 23 |
| azathioprine + sirolimus | Astellas Pharma | Approved | 85 |
| Itolizumab + EQ001 Placebo | Biocon | Phase 3 | 77 |
| EQ001 + EQ001 Placebo | Biocon | Phase 1/2 | 41 |
| SHR0302 | Jiangsu Hengrui Medicine | Phase 1 | 33 |
| Acalabrutinib | AstraZeneca | Phase 2 | 52 |
| Aspirin + Ticagrelor | AstraZeneca | Approved | 85 |
| Sugammadex | Merck | Approved | 85 |
| Ruxolitinib | Novartis | Approved | 85 |
| Imatinib Mesylate and Nilotinib | Novartis | Phase 2 | 52 |
| Prednisone + Jakavi(ruxolitinib) + Prednisone | Novartis | Phase 2 | 52 |
| PredEver | Novartis | Phase 2 | 52 |
| Lifitegrast 5% Ophthalmic Solution + Placebo | Novartis | Phase 1 | 33 |
| Cyclosporine | Novartis | Approved | 85 |
| Everolimus + Tacrolimus + Mycophenolic acid | Novartis | Approved | 85 |
| 1 + 2 | Novartis | Approved | 85 |
| Cyclosporine + Mycophenolate mofetil + Corticosteroids + Everolimus + Anti Thymocyte Globulin | Novartis | Approved | 85 |